Compare DCBO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | CRVS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.5M | 546.7M |
| IPO Year | 2020 | 2016 |
| Metric | DCBO | CRVS |
|---|---|---|
| Price | $18.56 | $20.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $34.67 | $28.00 |
| AVG Volume (30 Days) | 87.0K | ★ 7.5M |
| Earning Date | 02-27-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.42 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $236,691,000.00 | N/A |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $18.11 | $2.54 |
| 52 Week High | $43.84 | $26.95 |
| Indicator | DCBO | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 70.64 |
| Support Level | $18.11 | $20.70 |
| Resistance Level | $19.08 | $26.95 |
| Average True Range (ATR) | 0.71 | 2.08 |
| MACD | -0.19 | 1.37 |
| Stochastic Oscillator | 8.86 | 69.50 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).